|
|
 |
|
Viewing report
|
|
|
|
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
Bioseeker, Nov 2010, Pages: 777
This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma. BioSeeker has applied its unique drug assessment methodology to stratify the melanoma pipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of melanoma drugs is split between the 55% which have unique drug target strategies and the other part which have head-to-head target competing melanoma drugs in 32 different clusters. The latter has a competing ratio which is more than two times higher than the comparable average of the melanoma drugs in general. Contributing to this fact is heavily utilized drug target strategies like: IFNAR2, BARF and TUBB.
- Nine out of ten drug target strategies in Phase II development are new to melanoma drugs and at the same time the greatest numbers of new target strategies are found in Phase II (27%) and Phase I development (19%).
- Small molecules, antibodies and proteins are the dominating compound strategies of melanoma drugs, which represent almost three quarters of the entire pipeline. Cell therapy based melanoma drugs has the lowest representation of defined target strategy portfolio compared to that of other compound strategies of melanoma drugs.
- The highest number of described drug target strategies of melanoma drugs belongs to Pfizer, Novartis, Hoffmann-La Roche and Bristol-Myers Squibb.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any melanoma drug to ensure that the optimal market conditions exist by the time the product is commercialized.
Customers who bought this item also bought
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
Drug Delivery in Cancer - Technologies, Markets and Companies
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?
|
|
|
|
